Cancer drug trials used for regulatory approval are at risk of bias

Around half of trials that supported new cancer drug approvals in Europe between 2014 and 2016 were judged to be at high risk of bias, in a new study. Huseyin Naci,assistant professor of health policy a the London School of Economics joins us to talk about why potential bias may mean potential exaggeration of treatment effects, and could be costing our health systems a great deal of money. Read the full research: https://www.bmj.com/content/366/bmj.l5221 Listen on apple podcasts:

https://podcasts.apple.com/gb/podcast/the-bmj-podcast/id283916558?mt=2&app=podcast